DUBLIN--(BUSINESS WIRE)--The "House Dust Mite Allergy - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2020, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.
House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.
The Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 4 and 1 respectively.
House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Report Coverage
- House Dust Mite Allergy - Overview
- House Dust Mite Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- House Dust Mite Allergy - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- House Dust Mite Allergy - Companies Involved in Therapeutics Development
- Advagene Biopharma Co Ltd
- ALK-Abello AS
- Allergy Therapeutics Plc
- Anergis SA
- Astellas Pharma Inc
- Biomay AG
- Genetic Immunity Inc
- Polyrizon Ltd
- Roxall Medizin GmbH
- Stallergenes Greer plc
- Zhejiang I-Biological Technology Co Ltd
- House Dust Mite Allergy - Drug Profiles
- AD-17002 - Drug Profile
- House Dust Mite Allergy - Dormant Projects
- House Dust Mite Allergy - Discontinued Products
- House Dust Mite Allergy - Product Development Milestones
- Featured News & Press Releases
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/myrtn0